ArticleJournal of traditional and complementary medicine2026
Unveiling the mechanism of Baoyuan Jiedu Decoction in cancer cachexia-induced lipolysis through network pharmacology and bioinformatics.
Article in Journal of traditional and complementary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim: Baoyuan Jiedu Decoction (BJD) has demonstrated therapeutic potential against cancer-related cachexia (CC); however, its precise pharmacological mechanisms remain unclear. This study aims to elucidate the effects of BJD on CC-induced lipolysis and explore its underlying mechanisms. Experimental procedure: The chemical composition of BJD was characterized using UPLC-Q-TOF/MS and potential targets related to CC and lipolysis were identified through network pharmacology, bioinformatics analysis, and random forest analysis. The efficiencies and mechanisms of BJD were further confirmed in LLC tumor-bearing mice. Results and conclusion: We identified 120 active components in BJD and, by means of network pharmacology, bioinformatics and random forest analysis, identified PIK3R1 and HSP90AA1 as the key therapeutic targets. In LLC tumor-bearing mice, BJD significantly alleviated the symptoms of CC, reducing the serum levels of free fatty acids and glycerol. Furthermore, BJD downregulated the expression of HSP90AA1 and upregulated that of PIK3R1 in tumors. In iWAT and eWAT, BJD also decreased the expression of ATGL and p-HSL, indicating the inhibition of lipolysis induced by CC. These findings suggest that BJD mitigates lipolysis in CC through modulating PIK3R1 and HSP90AA1, providing valuable insights into its therapeutic mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.